anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an mRNA vaccine for treating lung cancer and bone metastasis thereof, and a preparation method and application thereof. Belongs to the technical field of nano-pharmaceutical preparations and nucleic acid vaccines. The vaccine can realize co-entrapment of the TLR4 agonist monophosphoryl lipid A (mPLA) and mRNA. The particle size is 60-600nm, the Zeta potential is +8 to +37mV, the encapsulation rate is 60-93 percent, and the drug-loading rate of mRNA is 7.5-20 percent. The mRNA vaccine constructed by the invention can be administrated through subcutaneous/muscle/nasal mucosa, the maturation of DCs cells is stimulated, M2 type macrophages are polarized into M1 type macrophages, the ADCC effect of NK cells is activated, and multiple immune channels cooperatively play the anti-tumor treatment effect. Particularly after the occurrence of the bone metastasis of the lung cancer, the vaccine can effectively inhibit the growth of the tumor, and activates the innate immunity and adaptive response of the organism by means of mPLA (methoxy-Poly-lactic acid) cooperative mRNA immunotherapy to cooperate with anti-tumor.
The invention discloses plant soaking lotion used for preventing losing hair and promoting growing hair, and a preparation and use method of the plant lotion and aims at overcoming the defects that existing medicine used for preventing losing the hair and promoting growing the hair is complicated in preparation, trouble to use, high in cost, slow to take effect and halfway in treatment and the like. The plant soaking lotion comprises 30 grams of cacumen biotae, 30 grams of mulberry root, 15 grams of folium mori, 50 grams of tuber fleeceflower stem, 15 grams of polygonum mulflorum, and 20 grams of tea bran which are blended uniformly, and 3000 milliliters of water is needed. The materials are soaked for 10 minutes and after being boiled, and stewed in slow fire for 20 minutes, the soaking lotion is obtained. 30 grams of soybean curb residue and 70 grams of ginger juice are blended uniformly to gain soybean curb residue ginger juice, the hair are washed by using the soaking lotion three times or four times, the hair and scalp are soaked in the soaking lotion for 15minutes, the soybean curb residue ginger juice is brushed on the head, the head is wrapped by a bag and after 20-30 minutes, and the head is washed. The soaking washing process is repeated once every 2-3 days. The soaking lotion has the advantages of preventing losing the hair and promoting growing the hair, having natural material components, and being simple in preparation, low in cost, and convenient to prepare and use, good in effect and free from side effect.
The invention relates to a method for treating chronic atrophic gastritis. According to the method, Radix Codonopsis, Radix Astragali,fried atractylodes, Poria cocos, Salvia chinensis,Smilax glabra, raw coix seeds, red sage root, costus root, coke hawthorn and medicated leaven, rice-grain sprout and malt and radix glycyrrhizae are used as main raw materials; for patients with interior accumulation of dampness and turbid, rhizoma atractylodis and cortex magnoliae officinalis are added; for patients with endoretention of damp heat, rhizoma coptidis from Sichuan of China and radix scutellariae are added; for patients with liver-stomach disharmony, radix bupleuri and rhizoma cyperi are added; and for patients with lack of stomach yin, ladybell root, glehnia root and dendrobium are added. The above medicines are decocted with water. One dose of the drug is used daily, once in the morning and once at night. Three months is a treatment course. The drug is taken for 2 treatment courses. The drug will have an obvious effect generally 6 months after drug withdrawal.
The invention relates to a medicine for treating esophageal cancer. China has high esophageal cancer rate, the number of people died from esophagus cancer is only second to that of people died from stomach cancer. At present, esophagus cancer is mainly treated by radiotherapy and chemotherapy, which have serious side effects. The medicine is prepared from dry powder of extracts of indigowoad root, euphorbia lunulata, artificial bezoar, sal ammoniac and clematis chineniss osbeck. The root of the pathomechanism of esophageal cancer lies in that the functions of the body decades due to weak Yang qi. Esophageal cancer is mainly treated by warming Yang, tonifying qi, strengthening vital energy and improving body functions. The treatment principle of traditional Chinese medicine is demonstrated in the invention. The medicine is capable of soothing liver, regulating qi, descending adverse qi, removing stasis, promoting blood circulation, removing stasis, softening hardness to dissipate stagnation, strengthening body resistance and archaeus, promoting the secretion of saliva or body fluid, moistening dryness, resolving phlegm, clearing heat, detoxifying, resisting cancer, relieving pain, warming Yang, tonifying qi and the like. Compared with other method for treating esophageal cancer, the medicine is relatively guaranteed and safe and has the advantages of stable dose and component, convenience for oral administration, and obvious treatment effect.
FIELD: medicine, infection diseases. SUBSTANCE: method involves administration of acyclovir during all period of epidemic outbreak and intake of acyclovir is carried out twice per a day in the dose by 200 mg for each intake. Invention promotes to prevention of development of clinical symptoms of influenza. Invention can be used for chemoprophylaxis of influenza. EFFECT: enhanced effectiveness of chemoprophylaxis. 2 cl, 4 ex
A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
PURPOSE: A hair conditioner is provided to be mixed with dimethyl polysiloxane, volatile silicon, and baobab seed oil to provide silky hair. CONSTITUTION: A hair conditioner comprises baobab seed oil, 15 mass% of decamethylcyclopentasiloxane, and dimethyl polysiloxane of which viscosity is over 4000 mPa·s. The viscosity of dimethyl polysiloxane is below 10000 mPa·s when 15 mass% of decamethylcyclopentasiloxane is added. The hair conditioner is used for treating hair. The hair conditioner does not need to be washed out. The hair conditioner is a non-aqueous system.
PROBLEM TO BE SOLVED: To prepare an artificial lachrymal fluid for ophthalmology, having excellent curing effect on dry eye by specifying both osmotic pressure and pH of the fluid through including metal ions which are included in a living body and comprise alkali metal ions as main ingredients and alkaline earth metal ions as auxiliary ingredients. SOLUTION: The objective artificial lachrymal fluid is prepared by including metal ions which are included in a living body and comprise (A) alkali metal ions as main ingredients and (B) alkaline earth metal ions as auxiliary ingredients so as for the osmotic pressure and pH value of the fluid to become respectively 220-295 OsmkgH2O (preferably 240-280 OsmkgH2O) and 6-8 (preferably 6.5-7.5). The ingredient A is e.g. Na+ or K+ and the ingredient B is e.g. Mg2+ or Ca2+. It is preferable that sodium chloride and potassium chloride are supply sources for Na+ and K+ respectively and that magnesium chloride and calcium chloride are supply sources for Mg2+ and Ca2+ respectively. The fluid may include Zn2+, caster oil or the like, if needed.
This is a 2-part study. Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Forty subjects will be randomized to treatment sequence to determine the order in which they will receive the tablet (test) or capsule (reference) formulation in the fasted state. Fourteen days will separate dosing in Period 1 and Period 2. After Part 1 is completed, the Part 1 pharmacokinetic blood samples will be shipped for bioanalysis. Study conduct will proceed to Part 2. Fourteen days will separate dosing in Part 1 Period 2 and Part 2 Period 1.

Part 2 is an open-label, randomized, Latin-square 2x2 crossover study. The approximately 40 subjects who participated in Part 1 will be randomized to treatment sequence to determine the order in which they will receive the tablet (test) formulation in the high fat fed state or the low fat fed state. Fourteen days will separate dosing in Period 1 and Period 2
All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
AIM: To assess temporal trends of chronic kidney disease (CKD) attributable to type 2 diabetes (T2D) globally and in five sociodemographic index (SDI) regions.
MATERIALS AND METHODS: We extracted the population data and CKD burden attributable to T2D from the Global Burden of Disease Study 2019. We evaluated the trends of disability-adjusted life years (DALYs), mortality, prevalence and incidence through age-period-cohort modelling, and calculated net drifts (overall annual percentage changes), local drifts (annual percentage changes in each age group), longitudinal age curves (fitted longitudinal age-specific rates), period relative risks (RRs) and cohort RRs.
RESULTS: From 1990 to 2019, the global burden of CKD attributable to T2D showed increasing trends in general. The burden of CKD attributable to T2D was highest in the middle SDI region and lowest in the low SDI region. Age effects increased with age, and peaked at the ages of 75-79 and 80-84 years for incidence and prevalence, respectively. Period RRs in the burden of CKD attributable to T2D increased, with the high SDI being the most remarkable in DALYs and mortality, and the middle SDI being the most notable in incidence. Cohort RRs showed unfavourable trends in incidence and prevalence among recent cohorts.
CONCLUSIONS: After a lengthy period of multi-initiative diabetes management, the high-middle SDI region exhibited improvement. However, unresolved issues and improvement gaps were still remarkable. Future efforts to reduce the burden of CKD attributable to T2D in the population should prioritize addressing the unfavourable patterns identified.
The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
During the 4\~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
Internal iliac artery (IIA) balloon occlusion catheters have been commonly inserted to decrease the risk of postpartum hemorrhage in placenta accreta spectrum disorders; however, there has been mixed success in clinical studies. Placement of an infrarenal aortic balloon has shown more consistent effectiveness in recent studies. A possible reason for this is collateral arterial supply to the placenta from external iliac artery branches. Retrospective chart review was conducted of angiography images during prophylactic IIA balloon occlusion catheter insertion over a 7-year period. Sixty-two individual cases were identified. Digital subtraction angiography (DSA) was performed in 32 (52%) cases, and 20 (62%) showed collateral blood supply from branches of the external iliac arteries, namely the round ligament artery. In conclusion, a high proportion of placenta accreta spectrum cases have arterial blood supply from branches of the external iliac artery, which may explain the discrepancy in effectiveness seen between IIA and infrarenal aortic sites of balloon occlusion catheter placement.
The invention relates to a method to quantify human corneal tissue parameters to improve biomechanical modelling of refractive and therapeutic procedures to reduce or eliminate refractive errors and unwanted wavefront aberrations. The analysis of the preoperative biomechanical properties of cornea assists in predicting the postoperative biomechanical response of cornea. The computational models of extreme properties of the corneal tissue are conducted and the 3-D finite element models are populated with tomographic information of the cornea and artificial intelligence is trained to consider the pre-operative characteristics of the corneal tissue. The post-operative refractive procedures are simulated using the said finite element models. Finally, biomechanical deformations are prospectively estimated and method builds a deep learning approach to link clinical features to changes in biochemical outcomes. The method predicts the post-operative biomechanics of the corneal tissue and derives long term postoperative biomechanical response of cornea.
Concomitant use of benzodiazepines, including Valium, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Valium concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Valium than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking Valium, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

Advise both patients and caregivers about the risks of respiratory depression and sedation when Valium is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug Interactions).
PURPOSE:To obtain a nail cosmetic by sealing nail coating agent into a microcapsule capable of readily disintegrating under pressure and coating a flexible tape having adhesive property with the microcapsule, applying the tape to a nail, fixing the tape on a finger, rubbing the tape on the nail and applying the coating agent in the capsule to the nail. CONSTITUTION:The aimed nail cosmetic obtained by sealing a nail coating agent (e.g. coating agent each using nitrocellulose as a film ingredient and using ethyl acetate, toluene, acetone or butyl acetate as a solvent) into a microcapsule (especially preferably microcapsule having 1-300 grain diameter, e.g. glycolic acid cellulose) and applying the microcapsule to soft tape having adhesive property. The attached part is applied to the nail and the tape is attached to a finger and fixed and the tape on the nail is rubbed to apply the coating agent onto the nail. The method is simple and can draw color pattern freely and the cosmetic is applied to nail without giving tense feeling to the nail, because the cosmetic is thin applied.
The invention provides a DcR3 polypeptide for treating infectious diseases and applications thereof. Concretely, DcR3 is a marker for indicating infectious inflammation with high specificity and sensitivity, and inhibition of DcR3 has effective treatment effects for infectious inflammation. The polypeptide of DcR3 is designed and synthesized for competitive inhibition of combination of apoptosis acceptors (such as Fas, HVEM/LT R, DR3, etc.) and apoptosis factors (FasL, LIGHT, TL1A, etc.), so that apoptosis pathway is blocked, and biological effects of infectious inflammation (such as septicemia) symptoms can be effectively reduced. In addition, experiments also show that when DcR3 and PCT are used as markers at the same time, specificity and sensitivity of early diagnosis of septicemia are improved.
In some examples, a word embedding is received. A word embedding includes a plurality of vectors in vector space. Each vector of the plurality of vectors represents a natural language word or other character sequence. Each vector is oriented in vector space based on a semantic similarity between each of the natural language word or other character sequence. A first distance is determined between a first vector and a second vector. A second distance is determined between a third vector and the second vector. Based at least in part on the first distance between the first vector and the second vector and the second distance between the third vector and the second vector, the third vector is moved closer or further away from the second vector. The moving is indicative of introducing a bias or removing a bias between the third vector and the second vector. This introducing or removing of bias supports more accurate and inclusive results from an application such as search of healthcare data, among other things.
All participants will undergo a single-stage SCS implantation procedure with 2 leads inserted in the posterior epidural space according to standard clinical practice. For ventral column stimulation SCS electrodes will be placed ventrally at T9/10 for upper abdominal pain and at T10/11 to T11/12 for lower abdominal pain.
New medicaments for treating nodular inflammation of the teats of ruminants (nodular thelitis) consist of (a) a combination of active substances exerting a specific action against Mycobacterium aquae and (b) a carrier material contg. dimethyl sulphoxide (I), which favours penetration fo the antibacterial substances into the wall of the teat. Used for treatment of nodular thelitis, a chronic condition of milk cows due to Mycobacterium aquae which manifests itself as one or more nodules in the subcutaneous connective tissue of the teats. The active substances used in combination in the new medicaments are pref. kanamycin (pref. as thesulphate), hexamidine isethionate, ionizid and diaminodiphenyl sulphone. Pref. carried materials contain 10 pts. (I) and 80 pts. of a mixt. of lanolin, "Lanette N" (RTM) and propylene glycol.
PURPOSE:Microspheres for controlling release of the third substance, obtained by packing the third substance into the hole part of porous powder and coating the surface of the powder with inorganic fine powder and/or organic fine powder. CONSTITUTION:The third substance (e.g., drug, food and drink, animal drug, agricultural chemical, fertilizer, etc.) is packed into the hole part of porous powder (e.g., porous cellulose, porous styrene resin, porous nylon, etc.) by dissolution in a solvent, blending, suspending, emulsification, etc. and the surface of the powder is coated with inorganic fine powder (e.g., titanium oxide, silica fine powder, various bentonites, aluminum oxide, etc.; preferably <=100mum particle diameter) and/or organic fine powder (e.g., methacrylate, polyethylene, nylon, etc.), to give microspheres. Since the properties and color of the microspheres can be controlled by regulating the kind and amount of the combination of the components, it is effective for various uses.
The mammalian body possesses remarkable adaptability to cold exposure, involving intricate adjustments in cellular metabolism, ultimately leading to thermogenesis. However, cold-induced stress can impact immune response, primarily through noradrenaline-mediated pathways. In our study, we utilized a rat model subjected to short-term or long-term mild cold exposure to investigate systemic immune response during the cold acclimation. To provide human relevance, we included a group of regular cold swimmers in our study. Our research revealed complex relationship between cold exposure, neural signaling, immune response, and thermogenic regulation. One-day cold exposure triggered stress response, including cytokine production in white adipose tissue, subsequently activating brown adipose tissue, and inducing thermogenesis. We further studied systemic immune response, including the proportion of leukocytes and cytokines production. Interestingly, γδ T cells emerged as possible regulators in the broader systemic response, suggesting their possible contribution in the dynamic process of cold adaptation. We employed RNA-seq to gain further insights into the mechanisms by which γδ T cells participate in the response to cold. Additionally, we challenged rats exposed to cold with the Toll-like receptor 2 agonist, showing significant modulation of immune response. These findings significantly contribute to understanding of the physiological acclimation that occur in response to cold exposure.
After dental extractions, patients may experience post-operative pain, with varying degree of severity among patients. The use of Er, Cr: YSGG laser in oral wound healing has garnered considerable interest and attention in recent years. The present study aims to evaluate and assess the wound healing and post operative pain after extraction of teeth in pediatric patients with application of Er, Cr: YSGG laser. Children aged 7-14 years of age with alteast one grossly decayed permanent molar indicated for extraction were included in the study. 60 teeth were randomly divided in two group- one receiving conventional treatment with post extraction pressure pack gauze and one receiving Er, Cr: YSGG laser bandage treatment. A post operative assessment was done by WBFPRS and Wound healing index for post operative pain and wound healing respectively on 24 h, 3rd, 7th and 14th day follow up. Er, Cr: YSGG laser bandage group showed statistically significant difference in both post operative pain and wound healing on follow ups. The study shows that application of laser bandage can be done in post operative extraction sockets to alleviate wound healing, decreasing post operative pain and discomfort.
Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
To evaluate the need for drug counseling aimed at reducing illicit drug use and increasing buprenorphine/naloxone adherence, the proposed study compares manual-guided Physician Management (PM) and PM combined with on-site manual-guided Cognitive Behavioral Therapy (CBT) in a 24 week randomized clinical trial of buprenorphine/naloxone in a heterogeneous population of opioid dependent patients (N=140) in a primary care clinic. PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services. CBT will be provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing buprenorphine/naloxone adherence. The study will test the hypothesis that that the addition of CBT to PM will lead to decreased illicit drug use, durable effects after counseling has been discontinued, improved buprenorphine/naloxone adherence and will demonstrate incremental cost-effectiveness in patients receiving buprenorphine/naloxone maintenance in primary care. Primary outcome measures include reductions in illicit opioid use and abstinence achievement, as assessed by weekly urine toxicology testing and self report. Secondary outcome measures include retention in treatment, reductions in cocaine use and HIV risk, decreased criminal activity and improved health and employment status. Utilization and costs of services, spillover effects in the PCC, and patient and staff perceptions of benefits and problems associated with primary care agonist maintenance treatment will also be evaluated. The results of this study will help define the role of professional evidence-based drug counseling in expanding access to treatment with buprenorphine/naloxone.